Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
SGMT Stock Chart & Stats
$5.55
-$0.58(-10.41%)
At close: 4:00 PM EST
$5.55
-$0.58(-10.41%)
Day’s Range― - ―
52-Week Range$1.73 - $11.41
Previous CloseN/A
Volume1.06M
Average Volume (3M)690.81K
Market Cap
$172.06M
Enterprise Value$139.68M
Total Cash (Recent Filing)$116.69M
Total Debt (Recent Filing)$115.00K
Price to Earnings (P/E)―
Beta2.73
Next Earnings
Mar 30, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding31,001,108
10 Day Avg. Volume1,105,656
30 Day Avg. Volume690,806
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)0.91
Price to Sales (P/S)0.00
P/FCF Ratio-3.32
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$27.00Price Target Upside386.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.93
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
China Commercial OpportunityRegulatory review and an accepted submission for an acne program in China could enable approval that triggers milestone payments and royalties, materially improving near-term revenue visibility.
Clinical Safety And EfficacyLate-stage and long-term studies reported a clean safety profile for denifanstat with no drug-related serious adverse events and continued reductions in acne lesion counts, supporting clinical confidence in the therapy.
Combination Therapy LicensingA global license for a novel resmetirom active ingredient combined with Phase 1 data showing good tolerability supports advancing a denifanstat–resmetirom fixed-dose strategy and strengthens the case for an oral competitive option in liver disease.
Bears Say
FDA Trial-design UncertaintyProgression to mid-stage development depends on favorable Phase 1 results and alignment with the FDA on study design, creating regulatory and development uncertainty that could affect timelines and outcomes.
Formulation Availability DelayUse of separate tablets in the mid-stage study means a co-formulated single-pill option would only be evaluated later, potentially delaying access to a convenient fixed-dose product for patients.
Tolerability ConcernsPrevious clinical data showed hair thinning occurred more often with active treatment than placebo, posing a tolerability risk that could limit patient acceptance and prescriber uptake.
Sagimet Biosciences, Inc. Class A News
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $1.73 and its highest was $11.41 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $172.06M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Mar 30, 2026 which is in 49 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Nov 13, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.386 by -$0.014.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.43.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 31,001,108 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.386. Following the earnings report the stock price went down -12.245%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sagimet Biosciences, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.00 (386.49% Upside)
$27.00 (386.49% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.83%
12-Months-Change
Fundamentals
Return on Equity
-39.78%
Trailing 12-Months
Asset Growth
-26.53%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
SGMT Stock 12 Month Forecast
Average Price Target
$27.00
▲(386.49% Upside)
Technical Analysis
Codexis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
10.06% Insiders
5.84% Mutual Funds
0.03% Other Institutional Investors
79.28% Public Companies and Individual Investors